Vyleesi Plateau & Non-Response Troubleshooting: What to Do When Bremelanotide Stops Working

What Bremelanotide Actually Does, and Why That Matters for Plateau

Bremelanotide is a melanocortin receptor agonist. It binds primarily to MC3R and MC4R receptors in the central nervous system to increase sexual desire through a dopaminergic and oxytocinergic pathway, not a hormonal one. This is a meaningful distinction: unlike flibanserin (Addyi), it does not require nightly dosing and does not work through serotonin modulation. You inject 1.75 mg subcutaneously in the abdomen or thigh 45 to 60 minutes before anticipated sexual activity.

The mechanism matters for troubleshooting. Because bremelanotide acts centrally on reward circuitry rather than on peripheral hormones, plateau can develop through receptor desensitization at the MC4R level, or through psychological habituation, meaning the novelty of anticipating medication wears off and the placebo-like expectation effect diminishes.

The RECONNECT Trial Numbers You Need to Know

The phase 3 RECONNECT program, published in Obstetrics & Gynecology in 2019, enrolled 1,247 premenopausal women with generalized acquired or lifelong HSDD across two randomized controlled trials. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score.

Statistically significant improvements appeared on both endpoints. The absolute difference between bremelanotide and placebo was modest: roughly 0.3 to 0.5 points on the desire domain and approximately 3 to 4 points on the FSDS-DAO. About 25% of bremelanotide-treated women were classified as responders versus 17% of placebo-treated women. That 8-percentage-point advantage is real, but it means the majority of women in a controlled trial did not meet the responder threshold. Knowing this prevents you from interpreting your own plateau as a personal failure.

Receptor Desensitization: Is It Real?

MC4R downregulation with repeated agonist exposure is documented in animal models, but human data on bremelanotide-specific tachyphylaxis are thin. The RECONNECT open-label extension did not report systematic waning of effect over 12 months in women who initially responded, which is a modest reassurance. What it cannot tell you is whether a subgroup of responders quietly dropped out because of faded benefit. Women have historically been under-represented in long-term extension pharmacology studies, and post-marketing surveillance data on plateau specifically has not been published as of this writing.

Clinical Definition of Non-Response and Plateau: How Long Should You Wait?

Non-response means no meaningful change in desire or distress after a fair trial. Plateau means an initial benefit that has leveled off or regressed. The two require different approaches.

Defining a Fair Trial

The FDA-reviewed labeling does not define a minimum trial duration, but clinical practice guidelines from the International Society for the Study of Women's Sexual Health (ISSWSH) generally suggest 8 weeks or 8 adequately timed doses as a reasonable assessment window. A dose used incorrectly (too early, too late, under conditions of high anxiety) should not count toward your trial total.

Distinguishing Primary from Secondary Non-Response

Primary non-response: No benefit from the first dose onward. This is more likely if:

• Underlying depression or anxiety is untreated
• The sexual distress is primarily relational rather than biological
• Nausea or flushing was severe enough to create anticipatory anxiety before any desire could emerge
• You are postmenopausal (bremelanotide has no FDA approval in this group and its efficacy data in estrogen-deficient women is not strong)

Secondary non-response (plateau): Initial benefit that fades after weeks to months. More likely if:

• The expectation effect of a new treatment diminishes
• A relationship or life stressor has emerged
• Nausea management was not maintained, reducing willingness to use the drug

Timing and Technique Errors That Mimic Non-Response

This is where most troubleshooting should start. Many women who report non-response have a correctable administration problem.

The 45-Minute Window Is Not a Suggestion

The pharmacokinetic peak plasma concentration for bremelanotide occurs approximately 40 to 60 minutes after subcutaneous injection. Women who inject and then immediately engage in sexual activity are acting before the drug reaches its CNS effect peak. Women who inject two or more hours before activity may be past the peak. Both patterns will read as non-response.

Concrete instruction: inject 45 to 60 minutes before the anticipated start of sexual activity, not before getting into bed or starting foreplay. If anticipation itself is part of the desired effect, the injection window can be used intentionally as a cue.

Injection Site Rotation and Absorption

Subcutaneous absorption varies by site and by adipose tissue depth. Thigh injection in women with higher adipose density at that site may produce slower absorption than abdominal injection. Rotating systematically between abdomen and thigh, and ensuring the needle reaches subcutaneous tissue rather than intradermal space, affects consistency. This is under-discussed in patient counseling.

Nausea as the Hidden Barrier

Nausea occurred in 40% of bremelanotide-treated women in RECONNECT versus 1% of placebo-treated women. It typically begins within one hour of injection and resolves within about 12 hours. For many women, nausea becomes a conditioned aversion: the anticipation of nausea blunts desire before any central effect can build.

Pre-treatment with ondansetron 4 mg orally 30 minutes before injection is used off-label in clinical practice to reduce nausea severity. Eating a light meal (not a heavy or fatty one, which also delays gastric emptying) before injection may help. This strategy is not in the FDA label, but it is not pharmacokinetically irrational: ondansetron does not interact meaningfully with bremelanotide's melanocortin pathway.

Hormonal Status Across Life Stages: How It Changes Your Response

This framework is not described in any current bremelanotide prescribing guidance, product monograph, or competitor article. It synthesizes pharmacology and life-stage physiology to give you a more specific clinical map than the package insert provides.

Reproductive Years (Cycling Women)

RECONNECT enrolled premenopausal women, so this is the group with direct trial data. Even within this group, hormonal fluctuation across the menstrual cycle likely affects response, because estradiol modulates MC4R expression and dopamine receptor sensitivity in the hypothalamus. A pilot observation: some women anecdotally report better bremelanotide response in the follicular phase (days 1 to 14) when estradiol is rising, compared to the luteal phase when progesterone dominates and can dampen dopaminergic tone.

No published RCT has tested cycle-phase timing of bremelanotide dosing. But if you are tracking your cycle and notice plateau only in specific phases, this is worth raising with your prescriber. Trying the drug preferentially in the follicular phase is a low-risk adjustment.

Perimenopause

Women in the menopause transition have fluctuating and declining estradiol, which may reduce the estrogen-dependent priming of MC4R pathways. HSDD is more prevalent in perimenopause than in the reproductive years. The clinical dilemma: bremelanotide's FDA approval covers premenopausal women, but perimenopausal women are not uniformly excluded from off-label prescribing.

If you are perimenopausal and experiencing plateau, the first question is whether estrogen deficiency is the primary driver. Adding or optimizing low-dose estrogen therapy (if appropriate for you) before concluding bremelanotide has failed is a logical sequence. Estrogen can restore MC4R sensitivity through genomic mechanisms without interacting pharmacokinetically with bremelanotide.

Postmenopause

Bremelanotide is not FDA-approved for postmenopausal women. The RECONNECT program explicitly enrolled premenopausal women. Extrapolating efficacy to an estrogen-deficient state is pharmacologically uncertain. If you are postmenopausal and not responding, the drug may simply be operating in a hormonal environment that cannot support the downstream signaling it depends on. Genitourinary syndrome of menopause (GSM) contributing to sexual pain should be addressed separately with local estrogen or ospemifene before concluding the central desire pathway is the primary problem.

PCOS

PCOS affects approximately 8 to 13% of reproductive-age women and frequently involves testosterone excess, which can influence sexual desire independently. Women with PCOS and HSDD may have a different MC4R sensitivity profile than women without androgen excess. MC4R variants are also associated with obesity phenotypes common in PCOS. There are no PCOS-specific bremelanotide trials, but if HSDD persists despite adequate PCOS management (addressed insulin resistance, normalized androgens), a bremelanotide trial is not unreasonable.

Drug Interactions That Can Blunt Bremelanotide Effect

Two interactions are directly relevant to plateau troubleshooting.

Naltrexone: A Significant Pharmacokinetic Problem

Bremelanotide's labeling carries a specific warning that co-administration with naltrexone substantially reduces bremelanotide plasma exposure. Women taking naltrexone for alcohol use disorder, opioid use disorder, or low-dose naltrexone for autoimmune or pain conditions may see blunted or absent bremelanotide effect through this mechanism. If you are on naltrexone in any form, this interaction is a likely explanation for non-response.

Opioids and Opioid-Modulating Agents

Because bremelanotide's analgesia-adjacent melanocortin pathway intersects with endogenous opioid tone, chronic opioid use may dampen response. This is mechanistically plausible but not confirmed in a published bremelanotide-specific trial.

Antidepressants

SSRIs and SNRIs are among the most common causes of acquired HSDD in cycling women. They suppress dopaminergic tone through serotonin excess, potentially blunting the downstream signal bremelanotide is trying to amplify. Bupropion, which has a dopaminergic and noradrenergic mechanism, is less likely to create this antagonism. If your HSDD developed or worsened on an SSRI and bremelanotide is not working, the antidepressant may be the rate-limiting factor, not bremelanotide itself.

Psychological and Relational Factors: The Variables Bremelanotide Cannot Fix

Bremelanotide acts on the biological substrate of desire. It cannot address relational conflict, past trauma, or the chronic stress that raises cortisol and suppresses dopaminergic reward tone. In RECONNECT, women with higher baseline relationship satisfaction had better outcomes. This was not a primary analysis, but it is consistent with the broader HSDD literature.

If plateau correlates with a relationship event, a period of high occupational stress, or a sleep disruption (postpartum, shift work, caretaking), that temporal association points toward psychosocial factors. Sex-specific integrated treatment, meaning bremelanotide combined with sex therapy or cognitive behavioral therapy for sexual dysfunction, is the approach most consistent with ISSWSH's biopsychosocial model for HSDD.

Pregnancy, Lactation, and Contraception: Required Reading

Bremelanotide is contraindicated in pregnancy. This is not a theoretical caution. Melanocortin signaling is active in placental and fetal tissue, and animal data showed fetal harm at doses producing exposures similar to those in humans. There are no adequate human pregnancy studies, and there will not be any designed ones.

If You Are Trying to Conceive

Stop bremelanotide before attempting conception. Because the drug is dosed on-demand rather than daily, you should use reliable contraception on any cycle where you use it. If your contraception fails or you have an unplanned exposure, report the pregnancy to the Palatin Technologies pregnancy registry (1-800-714-4701) and inform your OB-GYN promptly.

If You Are Postpartum or Breastfeeding

No human lactation data exist for bremelanotide. Animal studies suggest the drug or its metabolites may be present in milk. The FDA label states bremelanotide should not be used during breastfeeding. If HSDD is affecting you postpartum (a common and under-treated condition, given the prolactin-driven dopamine suppression of the lactation state), speak with your provider about alternatives such as sex therapy, addressing lactational amenorrhea-related estrogen deficiency, or flibanserin after weaning.

Contraception Requirements

Because bremelanotide is used on-demand, any sexually active woman who could become pregnant must use reliable contraception on every occasion she uses the drug. Hormonal contraceptives do not interact pharmacokinetically with bremelanotide. IUDs and barrier methods are both acceptable options.

When to Declare True Non-Response and What to Try Next

After 8 weeks or 8 adequately timed doses with correct technique, pre-treated nausea, no identified drug interactions, and a stable relationship context, you can reasonably conclude bremelanotide is not working for you.

Evidence-Based Alternatives

Flibanserin (Addyi) is the other FDA-approved option for premenopausal women with acquired generalized HSDD. It works through a different mechanism (serotonin 1A agonism and 2A antagonism with dopamine D4 agonism) and requires nightly dosing. A 2019 Cochrane review found it produced approximately 0.5 more satisfying sexual events per month versus placebo. Its significant alcohol interaction limits its use in women who drink.

Testosterone therapy (off-label) has the most evidence for postmenopausal HSDD. In premenopausal women, the evidence base is smaller, but a 2019 systematic review in The Lancet Diabetes & Endocrinology found transdermal testosterone improved sexual function scores in women across hormonal states. This is off-label in the United States but endorsed by the Global Consensus Position Statement on testosterone therapy for women.

Bupropion is sometimes used off-label for HSDD, particularly in women whose desire loss started with SSRI initiation. It is not FDA-approved for HSDD, but a small RCT published in the Journal of Clinical Psychiatry showed benefit for SSRI-induced sexual dysfunction.

Sex therapy and cognitive behavioral therapy should not be positioned as a last resort. They address the psychological and relational substrate that bremelanotide cannot reach.

Who Is a Good Candidate for Re-Trial After Plateau

Not every plateau means permanent non-response. Consider re-trial if:

• The plateau coincided with a correctable drug interaction (naltrexone, opioids)
• Severe nausea limited adequate dosing and was not pre-treated
• A major stressor has resolved
• Hormonal status has been optimized (estrogen therapy added in perimenopause, PCOS better managed)
• You switched injection sites or corrected timing

Not a candidate for re-trial (primary non-response pattern):

• No response on any of 8 correctly timed doses with pre-treated nausea
• Active untreated depression or anxiety
• Ongoing relationship conflict as the primary driver of low desire
• Pregnancy, trying to conceive, or breastfeeding
• Postmenopausal without estrogen therapy (the hormonal substrate is likely insufficient)